# Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil

> **NCT01514734** · PHASE4 · TERMINATED · sponsor: **Alcon Research** · enrollment: 9 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Brinzolamide/timolol maleate fixed combination

## Key facts

- **NCT ID:** NCT01514734
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Low recruitment rate
- **Last updated:** 2013-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514734, "Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01514734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*